利用加利福尼亚州基于人群的 SARS-CoV-2 调查界定长 COVID

IF 4.5 3区 医学 Q2 IMMUNOLOGY
{"title":"利用加利福尼亚州基于人群的 SARS-CoV-2 调查界定长 COVID","authors":"","doi":"10.1016/j.vaccine.2024.126358","DOIUrl":null,"url":null,"abstract":"<div><p><em>Background</em>: More than four years after the start of the COVID-19 pandemic, understanding of SARS-CoV-2 burden and post-acute sequela of COVID (PASC), or long COVID, continues to evolve. However, prevalence estimates are disparate and uncertain. Leveraging survey responses from a large serosurveillance study, we assess prevalence estimates using five different long COVID definitions among California residents. <em>Methods</em>: The California Department of Public Health (CDPH) conducted a cross-sectional survey that included questions about acute COVID-19 infection and recovery. A random selection of California households was invited to participate in a survey that included demographic information, clinical symptoms, and COVID-19 vaccination history. We assessed prevalence and predictors of long COVID among those previously testing positive for SARS-CoV-2 across different definitions using logistic regression. <em>Findings</em>: A total of 2883 participants were included in this analysis; the majority identified as female (62.5 %), and the median age was 39 years (interquartile range: 17–55 years). We found a significant difference in long COVID prevalence across definitions with the highest prevalence observed when participants were asked about incomplete recovery (20.9 %, 95 % confidence interval [CI]: 19.4–22.5) and the lowest prevalence was associated with severe long COVID affecting an estimated 4.9 % (95 % CI 4.1–5.7) of the participant population. Individuals that completed the primary vaccination series had significantly lower prevalence of long COVID compared to those that did not receive COVID vaccination. <em>Interpretation</em>: There were significant differences in the estimated prevalence of long COVID across different definitions. People who experience a severe initial COVID-19 infection should be considered at a higher probability for developing long COVID. <em>Funding</em>: Centers for Disease Control and Prevention - Epidemiology and Laboratory Capacity.</p></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0264410X24010405/pdfft?md5=8bced2f48de9cd2446694815a427f3ba&pid=1-s2.0-S0264410X24010405-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Defining long COVID using a population-based SARS-CoV-2 survey in California\",\"authors\":\"\",\"doi\":\"10.1016/j.vaccine.2024.126358\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><em>Background</em>: More than four years after the start of the COVID-19 pandemic, understanding of SARS-CoV-2 burden and post-acute sequela of COVID (PASC), or long COVID, continues to evolve. However, prevalence estimates are disparate and uncertain. Leveraging survey responses from a large serosurveillance study, we assess prevalence estimates using five different long COVID definitions among California residents. <em>Methods</em>: The California Department of Public Health (CDPH) conducted a cross-sectional survey that included questions about acute COVID-19 infection and recovery. A random selection of California households was invited to participate in a survey that included demographic information, clinical symptoms, and COVID-19 vaccination history. We assessed prevalence and predictors of long COVID among those previously testing positive for SARS-CoV-2 across different definitions using logistic regression. <em>Findings</em>: A total of 2883 participants were included in this analysis; the majority identified as female (62.5 %), and the median age was 39 years (interquartile range: 17–55 years). We found a significant difference in long COVID prevalence across definitions with the highest prevalence observed when participants were asked about incomplete recovery (20.9 %, 95 % confidence interval [CI]: 19.4–22.5) and the lowest prevalence was associated with severe long COVID affecting an estimated 4.9 % (95 % CI 4.1–5.7) of the participant population. Individuals that completed the primary vaccination series had significantly lower prevalence of long COVID compared to those that did not receive COVID vaccination. <em>Interpretation</em>: There were significant differences in the estimated prevalence of long COVID across different definitions. People who experience a severe initial COVID-19 infection should be considered at a higher probability for developing long COVID. <em>Funding</em>: Centers for Disease Control and Prevention - Epidemiology and Laboratory Capacity.</p></div>\",\"PeriodicalId\":23491,\"journal\":{\"name\":\"Vaccine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0264410X24010405/pdfft?md5=8bced2f48de9cd2446694815a427f3ba&pid=1-s2.0-S0264410X24010405-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0264410X24010405\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24010405","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在 COVID-19 大流行开始四年多之后,人们对 SARS-CoV-2 的负担和 COVID 急性后遗症 (PASC) 或长期 COVID 的认识仍在不断发展。然而,对流行率的估计存在差异和不确定性。利用一项大型血清监测研究的调查反馈,我们对加利福尼亚居民中使用五种不同的长COVID定义的流行率估计进行了评估。方法:加利福尼亚州公共卫生部 (CDPH) 开展了一项横断面调查,其中包括有关 COVID-19 急性感染和康复的问题。我们邀请随机抽取的加州家庭参与调查,调查内容包括人口统计学信息、临床症状和 COVID-19 疫苗接种史。我们使用逻辑回归法评估了不同定义的 SARS-CoV-2 检测阳性者中长期 COVID 的流行率和预测因素。研究结果本次分析共纳入 2883 名参与者,其中大多数为女性(62.5%),年龄中位数为 39 岁(四分位数间距:17-55 岁)。我们发现,不同定义的长COVID流行率存在显著差异,当参与者被问及未完全康复时,流行率最高(20.9%,95% 置信区间[CI]:19.4-22.5),而严重长COVID的流行率最低,估计影响4.9%(95% CI 4.1-5.7)的参与者。与未接种COVID疫苗的人群相比,完成初级疫苗接种系列的人群的长COVID发病率明显较低。解释:在不同定义的人群中,长效COVID的估计流行率存在明显差异。初次感染 COVID-19 的重症患者应被视为长效 COVID 的高发人群。资助:美国疾病控制和预防中心--流行病学和实验室能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Defining long COVID using a population-based SARS-CoV-2 survey in California

Background: More than four years after the start of the COVID-19 pandemic, understanding of SARS-CoV-2 burden and post-acute sequela of COVID (PASC), or long COVID, continues to evolve. However, prevalence estimates are disparate and uncertain. Leveraging survey responses from a large serosurveillance study, we assess prevalence estimates using five different long COVID definitions among California residents. Methods: The California Department of Public Health (CDPH) conducted a cross-sectional survey that included questions about acute COVID-19 infection and recovery. A random selection of California households was invited to participate in a survey that included demographic information, clinical symptoms, and COVID-19 vaccination history. We assessed prevalence and predictors of long COVID among those previously testing positive for SARS-CoV-2 across different definitions using logistic regression. Findings: A total of 2883 participants were included in this analysis; the majority identified as female (62.5 %), and the median age was 39 years (interquartile range: 17–55 years). We found a significant difference in long COVID prevalence across definitions with the highest prevalence observed when participants were asked about incomplete recovery (20.9 %, 95 % confidence interval [CI]: 19.4–22.5) and the lowest prevalence was associated with severe long COVID affecting an estimated 4.9 % (95 % CI 4.1–5.7) of the participant population. Individuals that completed the primary vaccination series had significantly lower prevalence of long COVID compared to those that did not receive COVID vaccination. Interpretation: There were significant differences in the estimated prevalence of long COVID across different definitions. People who experience a severe initial COVID-19 infection should be considered at a higher probability for developing long COVID. Funding: Centers for Disease Control and Prevention - Epidemiology and Laboratory Capacity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vaccine
Vaccine 医学-免疫学
CiteScore
8.70
自引率
5.50%
发文量
992
审稿时长
131 days
期刊介绍: Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信